1. Blood Center of Zhejiang Province, Hangzhou, Zhejiang 310052, China; 2. Key Laboratory of Blood Safety Research of Zhejiang Province, Hangzhou, Zhejiang 310052, China
Abstract：Objective To investigate the prevalence of hepatitis B virus ( HBV ) infection among volunteer blood donors in Hangzhou City, and to evaluate the residual risk of transfusion-transmitted HBV infections. Methods Data pertaining to volunteer blood donors in Hangzhou City from 2016 to 2019 were retrieved from the blood donor management system. Hepatitis B surface antigen ( HBsAg ) was detected by enzyme-linked immunosorbent assay ( ELISA ) and HBV DNA was detected using nucleic acid testing. The incidence/window period model was employed to assess the residual risk of HBV transmitted through transfusion from donors. Results The prevalence of HBV infections was 0.56% among the 320 755 first-time donors and 0.13% among the 279 816 repeat donors in Hangzhou City from 2016 to 2019, and a higher prevalence of HBV infection was detected among first-time donors than among repeat donors ( P<0.05 ). The residual risks of transfusion-transmitted HBV infection were 296.38 per million person-times ( 95%CI: 277.57 to 315.19 per million person-times ) and 98.79 per million person-times ( 95%CI: 87.15 to 110.43 per million person-times ) among first-time and repeat donors with positive HBsAg, and were 86.79 per million person-times ( 95%CI: 76.60 to 96.98 per million person-times ) and 28.93 per million person-times ( 95%CI: 22.63 to 35.23 per million person-times ) among first-time and repeat donors tested positive for HBV DNA, respectively. Conclusions There is still a residual risk of HBV infection transmitted through transfusion from blood donors in Hangzhou City. Nucleic acid testing may remarkably reduce the residual risk of transfusion-transmitted HBV infection in blood donors.
[1] ROTH W K.History and future of nucleic acid amplification technology blood donor testing[J]. Transfus Med Hemother,2019,46(2):67-75. [2] JAYAWAYDENA T,HOAD V,STYLES C,et al.Modelling the risk of transfusion-transmitted syphilis:a reconsideration of blood donation testing strategies[J].Vox Sang,2019,114(2):107-116. [3] LI L,HAN T,ZANG L,et al.The current incidence,prevalence,and residual risk of hepatitis B viral infections among voluntary blood donors in China[J/OL].BMC Infect Dis,2017,17(1)[2021-10-29].https://pubmed.ncbi.nlm.nih.gov/29212443.DOI:10.1186/s12879-017-2861-3. [4] LELIE N,VERMEULEN M,VAN DRIMMELEN H,et al.Direct comparison of three residual risk models for hepatitis B virus window period infections using updated input parameters[J].Vox Sang,2020,115(3):133-145. [5] YAND H,ANDERSON S A,FORSHEE R,et al.Modeling complete removal of risk assessment questions in the USA predicts the risk of HIV exposure in blood recipients could increase despite the use of nucleic acid testing[J].Vox Sang,2016,110(4):324-328. [6] AINLEY L I,HEWITT P E.Haematology patients and the risk of transfusion transmitted infection[J].Br J Haematol,2018,180(4):473-483. [7] WHO Expert Committee on Biological Standardization.WHO technical report series;No 1004[R].Geneva:WHO,2017. [8] CORRÊA A S M,LAMARÃO L M,VIEIRA P C M,et al.Prevalence,incidence and residual risk of transfusion-transmitted HBV infection before and after the implementation of HBV-NAT in northern Brazil[J/OL].PLoS One,2018,13(12)[2021-10-29].https://doi.org/10.1371/journal.pone.0208414. [9] BUSCH M P,BLOCH E M,KLEINMAN S.Prevention of transfusion-transmitted infections[J].Blood,2019,133(17):1854-1864. [10] O'BRIEN S F,YI Q L,FAN W,et al.Residual risk of HIV,HCV and HBV in Canada[J].Transfus Apher Sci,2017,56(3):389-391. [11] VELATI C,ROMANO L,PATI I,et al.Prevalence,incidence and residual risk of transfusion-transmitted hepatitis B virus infection in Italy from 2009 to 2018[J].Blood Transfus,2019,17(6):409-417. [12] 谢小琴,王芳.重庆地区无偿献血者HBV筛查结果及其阳性人群特征分析[J].中国输血杂志,2021,34(7):743-746. XIE X Q,WANG F.Analysis of HBV screening results and positive population characteristics of blood donors in Chongqing[J].Chin J Blood Transfus,2021,34(7):743-746.
